Immunohistochemical markers such as PRAME and p16 may further aid classification; PRAME is highly specific for melanoma and is uniformly negative in benign nodal nevi but positive (>50% tumor cells) in metastatic melanoma [12,13]. This evidence concerns the gene CDKN2A and melanoma.